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Abstract
Background Certolizumab pegol (CZP) is an Fc-free, PEGylated anti-tumor necrosis factor biologic.
Objectives To report 3-year outcomes from the CIMPACT (NCT02346240) phase 3, CZP in moderate to severe plaque
psoriasis, randomized controlled trial.
Methods Adults were randomized 3:3:3:1 to CZP 200 mg every other week (Q2W), CZP 400 mg Q2W, etanercept
biweekly or placebo. At Week 16, CZP- and etanercept-treated PASI 75 responders were re-randomized to CZP 200 mg
Q2W, CZP 400 mg Q4W, CZP 400 mg Q2W or placebo for maintenance treatment; PASI 75 non-responders entered an
open-label escape CZP 400 mg Q2W arm. Patients entering the open-label extension (OLE; Weeks 48–144) from blinded
treatment received CZP 200 mg Q2W.
Results Double-blinded results have been reported previously. 261 patients received 200 mg Q2W upon OLE entry.
PASI 75 response was maintained in patients continuing 200 mg Q2W treatment through Weeks 16–144 (Week 144:
96.2%). In patients dosed down at Week 48 (double-blinded 400 mg to 200 mg Q2W), PASI 75 decreased
(Week 48: 98.7%; Week 144: 85.9%). In patients who received placebo through Weeks 16–48, PASI 75 response
decreased (Week 48: 60.4%), then increased following Week 48 switch to 200 mg Q2W (Week 144: 95.1%). 48 and 36
patients initially randomized to 200 and 400 mg Q2W, respectively, were Week 16 PASI 75 non-responders and entered
the escape arm; at Week 144, 71.8% and 78.2% achieved PASI 75. No new safety signals were identified.
Conclusions Response to CZP was durable over three years; no new safety signals were identified.
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Introduction
Plaque psoriasis (PSO) is an immune-mediated inflammatory
disease that affects approximately 2–6% of adults in Western
countries.1–3 Biologic agents targeting tumor necrosis factor-al-
pha (TNF-a),4 interleukin (IL)-12/23,5 IL-23,6 IL-17A7 or IL-
17RA8 are now key to treatment.9–12 PSO requires life-long
management; therefore, it is important to understand long-term
efficacy of treatments. Nearly half of patients discontinue treat-
ment with their first biologic within three years.13 Switching
from one biologic to another has been associated with decreased
efficacy.14
Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-TNF
biologic approved for treatment of patients with moderate to
severe PSO, as well as for rheumatoid arthritis, psoriatic arthri-
tis, axial spondyloarthritis and Crohn’s disease.15,16 PEGylation
increases the half-life of CZP to 14 days,17 and because it is Fc-
free, CZP does not bind to the neonatal Fc receptor for
immunoglobulin G. Two prospective studies showed a lack of pla-
cental transfer of CZP from mothers to infants18 and no to minimal
transfer from plasma into breast milk.19 Furthermore, a pharma-
covigilance safety database analysis of pregnancy outcomes demon-
strated no teratogenic effect of CZP compared to the general
population in the US and EU, and no increased risk of fetal death.20
Efficacy of CZP in patients with moderate to severe PSO has
been investigated in three phase 3 trials: CIMPASI-1
(NCT02326298), CIMPASI-2 (NCT02326272) and CIMPACT
(NCT02346240).21–23 Pooled three-year safety data from these
trials, totalling 995 patients and 2231.3 patient-years (PY) of
exposure, found no new safety signals for CZP in PSO as com-
pared to previously reported data for CZP in other indications,
and to other anti-TNF medications approved for PSO. Risk of
treatment-emergent adverse events (TEAEs) did not increase
with longer CZP exposure, and the safety profiles of high and
low doses were similar.24 Three-year efficacy outcomes have also
been reported for the CIMPASI-1 and CIMPASI-2 trials.25
To date, 16- and 48-week efficacy outcomes have been reported
from CIMPACT,21 finding CZP to be efficacious compared with
placebo21–23 and etanercept (ETN) after 16 weeks of treatment,21
with durability of initial responses through to Week 48.21,26 Here,
we present three-year efficacy and safety data from CIMPACT.
Methods
Study design
CIMPACT was a 144-week, phase 3, randomized, double-
blinded, parallel-group, placebo- and active comparator-con-
trolled, multicenter study conducted in North America and Eur-
ope, which was completed on 17th December 2018. The full
study design and methods have been reported previously.21
Patients were randomized 3:3:3:1 to CZP 200 mg every other
week (Q2W) (CZP 400 mg Q2W loading dose at Weeks 0, 2 and
4), CZP 400 mg Q2W, ETN 50 mg twice weekly or placebo (al-
location ratio selected to minimize exposure to placebo). At
Week 16, CZP- and ETN-treated patients who achieved a 75%
improvement from baseline in their Psoriasis Area and Severity
Index (PASI; PASI 75) were re‑randomized to CZP 200 mg
Q2W, CZP 400 mg every four weeks (Q4W), CZP 400 mg
Q2W or placebo, depending on their initial treatment (Fig. 1).
Week 16 PASI 75 responders who were initially randomized to
placebo continued to receive double-blinded placebo.
Patients who achieved PASI 75 at Week 16 but did not achieve
PASI 50 (50% improvement from baseline in PASI) at any visit
after Week 16 until Week 48 of double-blinded treatment entered
the 96-week open-label extension (OLE) at that visit. These
patients received CZP 400 mg Q2W upon OLE entry.
PASI 75 non-responders at Week 16 entered an escape arm,
in which they received open-label CZP 400 mg Q2W for up to
128 weeks.
At Week 48, patients in the double-blinded maintenance
treatment arms entered the OLE and received open-label CZP
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200 mg Q2W (if they maintained ≥PASI 50 to Week 48), while
patients in the escape arm continued to receive open-label
CZP 400 mg Q2W. Dose adjustment was permitted at OLE study
visits, based on PASI response and investigator discretion (Fig. 1).
Patients
Adult patients (≥18 years of age) with moderate or severe PSO
for ≥6 months were enrolled. Full inclusion and exclusion crite-
ria have been previously published.21
Efficacy outcomes
Week 16 and Week 48 data have been reported previously for the
intent-to-treat population.21 Here, we report efficacy data through
144 weeks among patients who entered the OLE and received
CZP 200 mg Q2W at Week 48 after double-blinded maintenance
treatment (Fig. 1). We also report Week 16–144 efficacy out-
comes in patients randomized to placebo, CZP 200 mg Q2W or
CZP 400 mg Q2W at Week 0 who did not achieve PASI 75 at
Week 16 and entered the open-label escape arm. Patients who
relapsed between Weeks 16 and 48 are not described.
Reported outcomes include the proportions of patients achiev-
ing PASI 75, 90% improvement from baseline in PASI (PASI 90),
or Physician’s Global Assessment score of 0 or 1 (‘clear’ or ‘almost
clear’, with 2-point improvement from baseline; PGA 0/1). For
efficacy analyses, patients were grouped according to their treat-
ment group in the maintenance period and Week 48 dose alloca-
tion, irrespective of subsequent dose-switching.
Safety outcomes
Assessment of TEAEs is presented, defined as AEs occurring
while treatment was ongoing or up to 70 days after the last CZP
dose, regardless of the dose received. TEAEs were coded accord-
ing to the Medical Dictionary for Regulatory Activities (Med-
DRA) version 18.1. Serious TEAEs (SAEs) included all medical
occurrences that were life-threatening or led to death, initial inpa-
tient hospitalization, prolongation of hospitalization, congenital
Figure 1 CIMPACT (NCT02346240) study design. Prior to Week 0, there was a screening period of up to 5 weeks to determine eligibility
for study entry, obtain laboratory data, enable washout of medications not permitted for use during the study, and verify that doses of
NSAIDs and other pain relievers were stable. aLD of CZP 400 mg Q2W at Weeks 0, 2 and 4 or Weeks 16, 18 and 20; bPlacebo-treated
Week 16 PASI 75 responders continued to receive placebo, while other Week 16 PASI 75 responders were re-randomized. PASI 75 non-
responders from all initial treatment groups entered the open-label escape arm; cETN-treated Week 16 PASI 75 responders, after a 4-
week washout, were re-randomized 2:1 to CZP 200 mg Q2W (preceded by a CZP 400 mg LD at Weeks 16, 18 and 20) or placebo; dCZP
200 mg Q2W-treated Week 16 PASI 75 responders were re-randomized 2:2:1 to CZP 200 mg Q2W, CZP 400 mg Q4W, or placebo;
eCZP 400 mg Q2W-treated Week 16 PASI 75 responders were re-randomized 2:2:1 to CZP 200 mg Q2W, CZP 400 mg Q2W, or pla-
cebo; fPatients receiving double-blinded maintenance treatment who did not achieve PASI 50 at any visit entered the OLE at that visit
and initially received CZP 400 mg Q2W; gPatients who did not achieve PASI 50 having received CZP 400 mg Q2W for ≥16 weeks in the
escape arm or ≥12 weeks in the OLE were withdrawn; hDuring open-label treatment (Weeks 48–144), patients receiving CZP 200 mg
Q2Wmandatorily dose escalated to CZP 400 mg Q2W if they did not achieve PASI 50; patients could also dose escalate at the investiga-
tor’s discretion if they achieved 50≤PASI<75. Patients receiving open-label CZP 400 mg Q2W for ≥12 weeks could have their dose
decreased from Week 48 onwards at the investigator’s discretion if they achieved PASI 75. BW, twice weekly; CZP, certolizumab pegol;
ETN, etanercept; LD, loading dose; NSAID, non-steroidal anti-inflammatory drug; PASI, Psoriasis Area and Severity Index; PASI 50/75,
≥50%/75% improvement from baseline in PASI; Q2W, every 2 weeks; Q4W, every 4 weeks.
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anomalies or birth defects or resulted in persistent or significant
disability. Events deemed medically significant by the investigator
could also be recorded as SAEs, regardless of severity.
Safety data were analyzed for the combined CZP-treated
group, and separately for the CZP 200 mg Q2W and 400 mg
Q2W doses. Patients who received CZP 400 mg Q4W were com-
bined with the CZP 200 mg Q2W group. Patients who switched
dose could be counted in both CZP dose groups, but only once
in the combined CZP group. Adverse events and exposure time
were attributable to the dose most recently received. Exposure-
adjusted incidence rates are incidences of new cases per 100 PY.
Statistical analysis
Estimates for responder rates and confidence intervals (CIs)
were adjusted predicted probabilities from a logistic regression
model with factors for treatment group, region and prior bio-
logic exposure; due to the treatment groups included in these
analyses, estimates may differ from those previously presented.
Patients who were withdrawn having not achieved PASI 50,
either at or after Week 32 in the escape arm or after ≥12 weeks’
CZP 400 mg Q2W treatment in the OLE, were imputed as non-
responders at subsequent time points. All other missing data
were handled using the Markov Chain Monte Carlo (MCMC)
method for multiple imputation. Patients who withdrew prior
to Week 16 were not included. Results and associated 95% CIs
are summarized alongside observed case (OC) data in Table S1.
Results
Patient disposition and baseline characteristics
At Week 0, 559 patients were randomized for initial treatment
with CZP 200 mg Q2W, CZP 400 mg Q2W, ETN or placebo. At
Week 16, 308 PASI 75 responders were re-randomized (Fig. 2);
144 to CZP 200 mg Q2W, 44 to CZP 400 mg Q4W, 49 to
CZP 400 mg Q2W and 71 to placebo. Two patients who were ran-
domized to placebo at Week 0 achieved PASI 75 at Week 16 and
continued to receive placebo to Week 48. In total, 223 PASI 75 non-
responders entered the escape CZP 400 mg Q2W arm at Week 16.
Of the 559 patients randomized at Week 0, 24 discontinued prior to
Week 16, and two did not continue having completed Week 16.
Figure 2 Patient disposition and discontinuations in the CIMPACT initial, maintenance and open-label treatment periods. N = 559
patients were randomized at Week 0. Weeks 0–16: initial treatment period; Weeks 16–48: maintenance treatment period; Weeks 48–144:
OLE. Two patients who completed the initial treatment period did not continue to the maintenance treatment period, and six patients who
completed the maintenance treatment period did not enter the OLE. aDid not achieve PASI 50 at a visit during the maintenance period; at
Week 48, n = 2 patients who received double-blinded maintenance CZP 200 mg Q2W treatment, n = 1 who received CZP 400 mg Q4W,
and n = 2 who received CZP 400 mg Q2W were mandated to receive CZP 200 mg Q2W upon OLE entry, but instead received CZP
400 mg Q2W. CZP, certolizumab pegol; Esc, escape; ETN, etanercept; OLE, open-label extension; PASI 50/75, ≥50%/75% improvement
from baseline in Psoriasis Area and Severity Index; PBO, placebo; Q2W/Q4W, every 2/4 weeks.
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At Week 48, 472 patients entered the OLE: 261 patients
received CZP 200 mg Q2W upon OLE entry, 63 of whom
adjusted their dose at least once (24.1%); 211 patients received
CZP 400 mg Q2W upon OLE entry, 24 of whom adjusted their
dose at least once (11.4%). Of these, 396 (83.9%) completed the
OLE period. Demographics and baseline characteristics were bal-
anced across OLE treatment groups (Table 1).
Durability of response in patients entering the open-label
extension
Of the patients who completed Week 48 on double-blinded
treatment and were mandated to receive CZP 200 mg Q2W
upon OLE entry, 34 received placebo during Week 16–48 dou-
ble-blinded maintenance treatment, 122 received CZP 200 mg
Q2W, 41 received CZP 400 mg Q4W, and 48 received
CZP 400 mg Q2W.
At the end of the double-blinded maintenance treatment per-
iod (Week 48), the PASI 75 responder rate was 93.2%
among patients who received CZP 200 mg Q2W from Week 16,
92.7% for those receiving CZP 400 mg Q4W, and 98.7% for
those receiving CZP 400 mg Q2W (Fig. 3a). At Week 144,
after patients received CZP 200 mg Q2W in the OLE (with per-
mitted dose adjustment), PASI 75 and PASI 90 responder rates
were well maintained within the CZP 200 mg Q2W or CZP
400 mg Q4W-randomized patients, and declined following dose
reduction in the CZP 400 mg Q2W-randomized group (Fig. 3a
and b).
Responder rates improved from Week 48–144 in patients who
received placebo between Weeks 16 and 48 and then received
CZP 200 mg Q2W upon OLE entry; at Week 48, PASI 75
responder rates were 60.4%, increasing to 95.1% at Week 144
following CZP treatment during the OLE (Fig. 3a). The PASI 90
responder rate declined through Week 16–48 in these patients,
from 62.1% to 23.4%, and increased again to 75.7% at Week 144
(Fig. 3b).
These trends were reflected in the PGA 0/1 responder rates
(Table S1).
Long-term efficacy of CZP treatment in patients entering
the open-label escape arm at Week 16
Continued CZP treatment in patients who entered the CZP
400 mg Q2W escape arm at Week 16 led to improved response
rates at Weeks 48 and 144. Firstly, for patients who were initially
randomized to CZP 200 mg Q2W, 48/165 (29.1%) did not
achieve PASI 75 at Week 16 and entered the CZP 400 mg Q2W
escape arm. After 32 weeks of treatment with CZP 400 mg
Table 1 Demographics and baseline characteristics by maintenance and open-label treatment groups
Maintenance period treatment/open-label period treatment
PBO/CZP 200 mg
Q2W (N = 34)
CZP 200 mg Q2W/CZP
200 mg Q2W (N = 122)
CZP 400 mg Q4W/CZP
200 mg Q2W (N = 41)
CZP 400 mg Q2W/CZP
200 mg Q2W (N = 48)
Esc CZP 400 mg Q2W/CZP
400 mg Q2W (N = 177)
Age (years), mean  SD 45.7  12.7 43.4  12.4 49.5  15.5 44.1  12.6 47.3  12.9
Male, n (%) 23 (67.6) 83 (68.0) 27 (65.9) 32 (66.7) 122 (68.9)
Caucasian, n (%) 34 (100) 120 (98.4) 40 (97.6) 46 (95.8) 169 (95.5)
BMI (kg/m2), mean  SD 29.2  5.5 28.6  5.3 28.8  6.3 27.5  5.1 30.2  6.4
Weight (kg), mean  SD 88.0  20.1 86.0  17.6 86.0  23.1 81.7  17.5 91.2  22.0
PSO disease duration
(years), mean  SD
19.2  13.9 18.0  11.3 19.0  14.2 17.7  11.2 17.7  11.4
Concurrent PsA
(self-reported), n (%)
7 (20.6) 20 (16.4) 9 (22.0) 8 (16.7) 22 (12.4)
PASI, mean  SD 20.4  7.5 21.4  8.7 20.5  7.1 20.7  6.9 20.6  8.5
DLQI, mean  SD 15.4  8.1 13.3  7.3 12.7  6.4 15.4  7.5 14.3  7.4
BSA affected (%), median 17.5 23.0 24.0 24.5 21.0
PGA, n (%)
3: moderate 22 (64.7) 85 (69.7) 31 (75.6) 33 (68.8) 120 (67.8)
4: severe 12 (35.3) 37 (30.3) 10 (24.4) 15 (31.3) 57 (32.2)
Any systemic PSO
treatment, n (%)
20 (58.8) 88 (72.1) 31 (75.6) 37 (77.1) 128 (72.3)
Prior biologic therapy, n (%)
0 27 (79.4) 86 (70.5) 26 (63.4) 35 (72.9) 133 (75.1)
1 4 (11.8) 28 (23.0) 14 (34.1) 12 (25.0) 35 (19.8)
2 3 (8.8) 8 (6.6) 1 (2.4) 1 (2.1) 9 (5.1)
Prior anti-TNF-a, n (%) 2 (5.9) 6 (4.9) 1 (2.4) 0 6 (3.4)
BSA, body surface area; BMI, body mass index; CZP, certolizumab pegol; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index;
PBO, placebo; PGA, Physician’s Global Assessment; PsA, psoriatic arthritis; PSO, psoriasis; Q2W, every 2 weeks; Q4W, every 4 weeks; SD, standard devia-
tion; TNF, tumor necrosis factor.
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Q2W, 59.0% of these patients achieved PASI 75 and 28.8%
achieved PASI 90. Following 128 weeks, 71.8% achieved PASI 75
and 42.7% achieved PASI 90 (Fig. 4, Table S1).
Secondly, for patients initially randomized to CZP 400 mg
Q2W, 36/167 (21.6%) did not achieve PASI 75 at Week 16 and
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Figure 3 PASI 75 and PASI 90 response rates by maintenance treatment group to Week 144 in patients who received CZP
200 mg Q2W upon OLE entry: (a) PASI 75; (b) PASI 90. Patients were included irrespective of initial treatment period (both Fig-
ure 3a and b). Patients who achieved PASI 75 at Week 16, remained on double-blinded treatment through to Week 48, and were
mandated to receive CZP 200 mg Q2W upon OLE entry were included. Patients who were withdrawn having not achieved PASI 50
from Week 32 onwards were imputed as non-responders at all subsequent time points. All other missing data were handled using
the MCMC method for multiple imputation. aDose adjustments were either mandatory or at investigator discretion, depending on
PASI response. Two patients who received CZP 200 mg Q2W during maintenance treatment, one who received CZP 400 mg Q4W,
and two who received CZP 400 mg Q2W and were mandated to receive CZP 200 mg Q2W upon OLE entry received CZP 400 mg
Q2W instead. Of those patients who received CZP 200 mg Q2W upon OLE entry, 9/34 (26.5%) patients who received placebo from
Week 16–48, 19/120 (15.8%) who received CZP 200 mg Q2W from Week 16–48, 7/40 (17.5%) who received CZP 400 mg Q4W
from Week 16–48, and 7/46 (15.2%) who received CZP 400 mg Q2W from Week 16–48 adjusted their dose at least once during
the OLE. CZP: certolizumab pegol; MCMC: Markov Chain Monte Carlo; OLE: open-label extension; PASI 75/90: ≥75%/90%
improvement from baseline in Psoriasis Area and Severity Index; PBO: placebo; Q2W: every 2 weeks; Q4W: every 4 weeks.
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patients achieved PASI 75 after 32 additional weeks’ CZP
400 mg Q2W treatment and 37.8% achieved PASI 90. This
response was sustained through Week 144, with 78.2% achieving
PASI 75 and 44.4% achieving PASI 90 after 128 additional
weeks’ CZP 400 mg Q2W treatment (Fig. 4, Table S1).
Of the 57 patients initially randomized to placebo, 53 (93.0%)
did not achieve PASI 75 at Week 16 and entered the CZP
400 mg Q2W escape arm. After 32 weeks’ CZP 400 mg Q2W
treatment, 71.8% achieved PASI 75 and 52.8% achieved PASI
90. Following 128 weeks’ CZP treatment, 74.4% achieved PASI
75 and 49.0% achieved PASI 90 (Fig. 4, Table S1).
These trends were reflected in the PGA 0/1 responder rates
(Table S1).
In the subgroups of patients entering the escape arm who
achieved <PASI 50 or 50≤PASI<75 at Week 16, PASI 75
response rates generally increased to Week 144 through
128 weeks of continued CZP treatment (Fig. S2).
Safety assessments
Through 144 weeks, 373 patients received ≥1 dose of CZP
200 mg Q2W and 412 patients received ≥1 dose of CZP 400 mg
Q2W, totalling 632 and 592 PY of exposure, respectively; total
exposure to CZP at any dose was 1224 PY (Table 2). During the
study, 446 patients (81.8%) experienced at least one TEAE
(Table 2), and 86 (15.8%) experienced a serious TEAE. Inci-
dence rates of TEAEs did not increase over time as compared to
previously reported data.21 Three deaths occurred, all during the
OLE: one case of acute myocardial infarction in a patient receiv-
ing CZP 200 mg Q2W, considered related to study treatment by
the investigator in a patient with BMI ≥30 kg/m2 at the time of
the event, with pre-existing hypertension, atherosclerosis and
ongoing tobacco use; two deaths considered unrelated to study
treatment by the investigators, including one case of craniocere-
bral injury in a patient receiving CZP 400 mg Q2W and one case
of chronic obstructive pulmonary disease in a patient receiving
CZP 200 mg Q2W. Incidences of TEAEs were similar across the
two dose groups (Table 2).
The most common TEAEs in patients receiving CZP were
nasopharyngitis (20.4%), upper respiratory tract infection
(13.8%) and hypertension (8.1%).
Opportunistic infections occurred in three patients (0.6%),
including one case of active tuberculosis in a patient receiving
escape CZP 400 mg Q2W (0.2%) during the maintenance per-
iod. One patient (0.2%) experienced primary progressive multi-
ple sclerosis while receiving CZP 400 mg Q2W. Malignancies
occurred in six patients (1.1%), including one case each of
anaplastic oligodendroglioma, basal cell carcinoma, breast can-
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Figure 4 Evolution of PASI 75 responder rates to Week 144 in patients who entered the open-label CZP 400 mg Q2W escape arm as
PASI 75 non-responders at Week 16. Patients included did not achieve PASI 75 at Week 16 and entered the open-label
CZP 400 mg Q2W escape arm. Patients who were withdrawn having not achieved PASI 50 from Week 32 onwards were imputed as
non-responders at all subsequent time points. All other missing data were handled using the MCMC method for multiple imputation.
aDose adjustments were either mandatory or at investigator discretion, depending on PASI response. 34 patients received CZP 200 mg
Q2W to Week 16, entered the escape arm and then entered the OLE at Week 48 (14 did not enter the OLE), of whom 4 adjusted their dose
at least once (11.8%). 29 patients received CZP 400 mg Q2W to Week 16, entered the escape arm and then entered the OLE at Week 48
(7 did not enter the OLE), of whom 6 adjusted their dose at least once (20.7%). 45 patients received PBO to Week 16, entered the escape
arm and then entered the OLE at Week 48 (8 did not enter the OLE), of whom 11 adjusted their dose at least once (24.4%). CZP, cer-
tolizumab pegol; MCMC, Markov Chain Monte Carlo; OLE, open-label extension; PASI 50/75, ≥50%/75% improvement from baseline in
Psoriasis Area and Severity Index; PBO, placebo; Q2W, every 2 weeks.
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Table 2 Summary of TEAEs through the initial, maintenance and open-label periods (safety set)
CZP 200 mg Q2Wa
(N = 373)




Total exposure, PY 632 592 1224
n (%) IR/100 PY (95% CI) n (%) IR/100 PY (95% CI) n (%) IR/100 PY (95% CI)
TEAEs overview
All TEAEs 276 (74.0) 129.5 (114.6, 145.7) 299 (72.6) 132.7 (118.1, 148.7) 446 (81.8) 119.8 (109.0, 131.5)
TEAEs leading to death 2 (0.5) 0.3 (0.0, 1.1) 1 (0.2) 0.2 (0.0, 0.9) 3 (0.6) 0.2 (0.1, 0.7)
SAEs 37 (9.9) 6.3 (4.4, 8.7) 51 (12.4) 9.4 (7.0, 12.4) 86 (15.8) 7.7 (6.1, 9.5)
TEAEs leading to discontinuation 19 (5.1) 3.0 (1.8, 4.7) 27 (6.6) 4.6 (3.0, 6.7) 45 (8.3) 3.7 (2.7, 5.0)
Treatment-related TEAEs 77 (20.6) 14.2 (11.2, 17.8) 77 (18.7) 15.2 (12.0, 19.0) 136 (25.0) 13.5 (11.3, 16.0)




SIEs 8 (2.1) 1.3 (0.6, 2.5) 10 (2.4) 1.7 (0.8, 3.2) 18 (3.3) 1.5 (0.9, 2.4)
Opportunistic infections 1 (0.3) 0.2 (0.0, 0.9) 2 (0.5) 0.3 (0.0, 1.2) 3 (0.6) 0.2 (0.1, 0.7)
Active TB 0 0 1 (0.2)b 0.2 (0.0, 0.9) 1 (0.2) 0.1 (0.0, 0.5)
Fungal esophagitis 1 (0.3) 0.2 (0.0, 0.9) 0 0 1 (0.2) 0.1 (0.0, 0.5)
Bacteremiac 0 0 1 (0.2) 0.2 (0.0, 0.9) 1 (0.2) 0.1 (0.0, 0.5)
All malignancies 4 (1.1)d 0.6 (0.2, 1.6) 4 (1.0)e 0.7 (0.2, 1.7) 6 (1.1) 0.5 (0.2, 1.1)
Malignancies excluding NMSC 4 (1.1) 0.6 (0.2, 1.6) 2 (0.5) 0.3 (0.0, 1.2) 5 (0.9) 0.4 (0.1, 1.0)
NMSC 0 0 2 (0.5) 0.3 (0.0, 1.2) 2 (0.4) 0.2 (0.0, 0.6)
MACE 2 (0.5) 0.3 (0.0, 1.1) 3 (0.7) 0.5 (0.1, 1.5) 5 (0.9) 0.4 (0.1, 1.0)
Cardiac failure 0 0 1 (0.2) 0.2 (0.0, 0.9) 1 (0.2) 0.1 (0.0, 0.5)
Acute coronary syndrome 0 0 1 (0.2) 0.2 (0.0, 0.9) 1 (0.2) 0.1 (0.0, 0.5)
Acute myocardial infarction 1 (0.3) 0.2 (0.0, 0.9) 0 0 1 (0.2) 0.1 (0.0, 0.5)
Angina pectoris 1 (0.3) 0.2 (0.0, 0.9) 0 0 1 (0.2) 0.1 (0.0, 0.5)
Extradural hematoma 0 0 1 (0.2) 0.2 (0.0, 0.9) 1 (0.2) 0.1 (0.0, 0.5)
Demyelinating-like disorders 0 0 1 (0.2) 0.2 (0.0, 0.9) 1 (0.2) 0.1 (0.0, 0.5)
Primary progressive multiple sclerosis 0 0 1 (0.2)f 0.2 (0.0, 0.9) 1 (0.2) 0.1 (0.0, 0.5)
Serious psoriatic conditions 2 (0.5) 0.3 (0.0, 1.1) 2 (0.5) 0.3 (0.0, 1.2) 4 (0.7) 0.3 (0.1, 0.8)
Psoriasis 1 (0.3) 0.2 (0.0, 0.9) 0 0 1 (0.2) 0.1 (0.0, 0.5)
Erythrodermic psoriasis 0 0 1 (0.2) 0.2 (0.0, 0.9) 1 (0.2) 0.1 (0.0, 0.5)
Guttate psoriasis 0 0 1 (0.2) 0.2 (0.0, 0.9) 1 (0.2) 0.1 (0.0, 0.5)
Pustular psoriasis 1 (0.3) 0.2 (0.0, 0.9) 0 0 1 (0.2) 0.1 (0.0, 0.5)
Serious bleeding events 1 (0.3) 0.2 (0.0, 0.9) 3 (0.7) 0.5 (0.1, 1.5) 4 (0.7) 0.3 (0.1, 0.8)
Hypersensitivity reactions and
anaphylactic reactions
0 0 0 0 0 0
Injection site reactions 4 (1.1) 0.6 (0.2, 1.6) 6 (1.5) 1.0 (0.4, 2.2) 10 (1.8) 0.8 (0.4, 1.5)
Hepatic events 31 (8.3) 5.2 (3.6, 7.4) 36 (8.7) 6.5 (4.6, 9.0) 62 (11.4) 5.5 (4.2, 7.0)
Lupus and lupus-like events 0 0 0 0 0 0
Hematopoietic cytopenia 0 0 0 0 0 0
No cases of congenital anomalies/birth defects were reported.
CI, confidence interval; CZP, certolizumab pegol; IR, incidence rate; MACE, major adverse cardiovascular event; NMSC, non-melanoma skin cancers; PY,
patient-years; Q2W, every 2 weeks; SAE, serious TEAE; SIE, serious infection event; TB, tuberculosis; TEAE, treatment-emergent adverse event.
a Includes CZP 400 mg Q4W.
b One case of active TB reported in a patient who received etanercept during the initial 16-week period before escaping to CZP 400 mg Q2W (TB was diag-
nosed 172 days after etanercept initiation, 60 days after CZP initiation, and the patient was discontinued from the study; before study entry, the QuantiFERON
TB GOLD test was negative and chest X-ray was normal; the patient lived in a country with a high prevalence of TB).
c Bacteremia secondary to Eggerthella lenta, did not lead to permanent discontinuation, was not considered related to study medication by the investigator,
and was resolved.
d Includes one case of breast cancer, one case of glioblastoma, one case of Hodgkin’s disease, and one case of laryngeal cancer.
e Includes one case of anaplastic oligodendroglioma, one case of clear cell renal carcinoma, one case of basal cell carcinoma, and one case of keratoacanthoma.
f The patient’s medical history indicated that symptoms pre-dated study entry.
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keratoacanthoma and laryngeal cancer (Table 2). No cases of
hypersensitivity reactions, anaphylactic reactions, lupus or
lupus-like events or hematopoietic cytopenia occurred.
Discussion
Over the course of three years’ CZP treatment, improvements in
signs and symptoms of moderate to severe PSO were well main-
tained. These data suggest that patients may be able to avoid
treatment switching due to loss of efficacy over a longer time
period, as is common with some biologic agents for treating
PSO;13,27 21% of patients discontinue adalimumab within three
years due to loss of efficacy, while 24% discontinue infliximab
and 45% discontinue ETN within three years for the same rea-
son.13 The patient groups analyzed here included patients who
responded to ETN treatment during the initial treatment period;
high Week 48 PASI response rates have also been reported pre-
viously in the subgroup of patients who switched from ETN to
CZP at Week 16.21 This suggests prior treatment with ETN does
not impact CZP efficacy.
The maintenance of response results seen in this trial are also
consistent with the long-term efficacy reported for CZP in other
indications (rheumatoid arthritis, psoriatic arthritis, Crohn’s
disease, axial spondyloarthritis),26,28–30 and with those published
for the CIMPASI-1 and CIMPASI-2 phase 3 trials.25 Responder
rates were high and numerically greater at Week 48 in patients
receiving double-blinded CZP 400 mg Q2W than in patients
receiving CZP 200 mg Q2W or CZP 400 mg Q4W (PASI 75:
98.7% versus 93.2% and 92.7%, respectively), suggesting that a
higher CZP dose may be beneficial in some patients. Response
rates were maintained through the OLE to Week 144 in patients
originally treated with CZP 200 mg Q2W. In the group whose
dose was lowered from CZP 400 mg Q2W to 200 mg Q2W
upon OLE entry, some patients had a reduced response, suggest-
ing that a proportion of patients may benefit from continued
treatment at a higher dose. This was particularly notable when
considering the higher response threshold of PASI 90. Because
there are many approved therapies for psoriasis with different
properties, many factors need to be considered when selecting
the optimal therapy for an individual patient;31,32 future research
should aim to establish which subgroups most benefit from
treatment with the 400 mg Q2W CZP dose.
Continuation of CZP treatment at the higher dose of 400 mg
Q2W may also be a viable treatment strategy in patients who ini-
tially do not respond, or partially respond, to treatment. In this
study, 59.0% of patients who did not achieve a PASI 75 response
after 16 weeks’ treatment with CZP dosed at 200 mg Q2W, and
79.7% of those dosed at 400 mg Q2W, achieved PASI 75 after
32 weeks’ further treatment with CZP 400 mg Q2W. These
responses were maintained or further improved to Week 144
(71.8% and 78.2%, respectively).
The three-year safety results presented here show that risk of
TEAEs does not increase with longer exposure to CZP as
compared to previously reported Week 48 data from the CIM-
PACT trial,21 and no new safety signals were identified as com-
pared to previously reported data for CZP, and to other anti-
TNF medications approved for PSO.33–35 This is consistent with
a pooled safety analysis of the CIMPACT, CIMPASI-1 and CIM-
PASI-2 trials over three years of CZP treatment,24 which also
found no increased risk of TEAEs with increased exposure, and
identified no new safety signals.
One limitation of this study was the possibility for patients
to adjust dose during the OLE, and the implication of this on
efficacy analyses of long-term dosing. Dose-switching could
occur multiple times, based on PASI response and the investiga-
tor’s discretion; 24.1% of patients who received CZP 200 mg
Q2W upon OLE entry, as well as 11.4% who received CZP
400 mg Q2W, switched dose at least once. Although this com-
plicates interpretation of long-term data, allowing dose adjust-
ment reflects real-world clinical practice. Additionally, despite
dose-switching, in all active treatment arms there was evidence
of long-term durability of response. However, due to the speci-
fic restrictions and conditions associated with changes in CZP
dose in this trial, the dose adjustments seen may not fully
reflect all situations in which dose adjustment may occur in
clinical treatment of patients with PSO. Therefore, results from
this trial do not allow a conclusion to be drawn regarding
which specific patients require increases and decreases in CZP
dose. Re‑randomization at Week 16, combined with the dose-
switching and multiple treatment arms, also meant that each
unique treatment path had a small sample size. This also com-
plicates interpretation and analysis, although again this may
reflect real-world treatment sequences, as disease flares and
recedes. Finally, while PASI 75 was the standard response level
used to define endpoints in PSO clinical trials when the CIM-
PACT study was designed, PASI 90 is now deemed more suit-
able as a robust response level to support treatment decisions.
PASI 90 results are reported here; however, these were not the
focus of the study and power calculations were based on
PASI 75 rather than PASI 90 responses.
Overall, CZP offers long-term clinical efficacy in patients with
moderate to severe PSO. Skin responses were durable in patients
receiving either dose of CZP from Week 16 to Week 144, and no
new safety signals were identified as compared to previously
reported data.
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